West Pharmaceutical Services, Inc. Earnings Recaps
Q3 2025
Oct 23, 2025
West's Q3 2025 results exceeded expectations with revenues up 5% to $805 million and adjusted EPS rising 6% to $1.96, prompting an increase in FY 2025 guidance.
Key takeaways
- Proprietary Products segment delivered $648 million in revenues, a 5.1% organic increase, driven by strong HVP components related to GLP-1 sales.
- Adjusted operating margins improved to 21.1%, underscoring operational efficiency.
- The company has 375 ongoing Annex 1 upgrade projects, boosting growth expectations from 150 to 200 basis points in 2025.
- Contract Manufacturing segment revenues grew 4.9% organically, benefiting from consolidation efforts in Arizona.
- Leadership transitions, including a new CFO and CTO, are strategically positioned to enhance innovation and operational growth.
Q2 2025
Jul 25, 2025
West Pharmaceutical Services reported strong Q2 2025 results, with net sales increasing 9.2%, driven primarily by robust growth in HVP components and GLP-1 elastomer products.
Key takeaways
- Net sales rose 9.2%, with 6.8% organic growth, reflecting strong customer demand and normalization of ordering patterns.
- Proprietary Products segment grew 8.4% organically, propelled by an 11.3% increase in HVP components tied to GLP-1 elastomer demand.
- Strong performance in HVP Delivery Devices segment saw a revenue increase of 30%, primarily due to Daikyo Crystal Zenith systems.
- Full-year 2025 guidance for organic revenue and adjusted EPS has been increased based on Q2 performance and favorable FX trends.
- West is proactively addressing capacity constraints in Europe with hiring and training initiatives to enhance production efficiency.